157 related articles for article (PubMed ID: 7710954)
1. Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone.
Lissoni P; Barni S; Meregalli S; Fossati V; Cazzaniga M; Esposti D; Tancini G
Br J Cancer; 1995 Apr; 71(4):854-6. PubMed ID: 7710954
[TBL] [Abstract][Full Text] [Related]
2. A randomized study of tamoxifen alone versus tamoxifen plus melatonin in estrogen receptor-negative heavily pretreated metastatic breast-cancer patients.
Lissoni P; Ardizzoia A; Barni S; Paolorossi F; Tancini G; Meregalli S; Esposti D; Zubelewicz B; Braczowski R
Oncol Rep; 1995 Sep; 2(5):871-3. PubMed ID: 21597833
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of tamoxifen plus melatonin in metastatic solid tumour patients.
Lissoni P; Paolorossi F; Tancini G; Ardizzoia A; Barni S; Brivio F; Maestroni GJ; Chilelli M
Br J Cancer; 1996 Nov; 74(9):1466-8. PubMed ID: 8912546
[TBL] [Abstract][Full Text] [Related]
4. Reversal of clinical resistance to LHRH analogue in metastatic prostate cancer by the pineal hormone melatonin: efficacy of LHRH analogue plus melatonin in patients progressing on LHRH analogue alone.
Lissoni P; Cazzaniga M; Tancini G; Scardino E; Musci R; Barni S; Maffezzini M; Meroni T; Rocco F; Conti A; Maestroni G
Eur Urol; 1997; 31(2):178-81. PubMed ID: 9076462
[TBL] [Abstract][Full Text] [Related]
5. Total pineal endocrine substitution therapy (TPEST) as a new neuroendocrine palliative treatment of untreatable metastatic solid tumor patients: a phase II study.
Lissoni P; Malugani F; Brivio F; Piazza A; Vintimilla C; Giani L; Tancini G
Neuro Endocrinol Lett; 2003; 24(3-4):259-62. PubMed ID: 14523367
[TBL] [Abstract][Full Text] [Related]
6. Oncostatic activity of pineal neuroendocrine treatment with the pineal indoles melatonin and 5-methoxytryptamine in untreatable metastatic cancer patients progressing on melatonin alone.
Lissoni P; Rovelli F; Frassineti A; Fumagalli L; Malysheva O; Conti A; Maestroni G
Neuro Endocrinol Lett; 2000; 21(4):319-323. PubMed ID: 11455367
[TBL] [Abstract][Full Text] [Related]
7. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil-containing combinations.
Cerea G; Vaghi M; Ardizzoia A; Villa S; Bucovec R; Mengo S; Gardani G; Tancini G; Lissoni P
Anticancer Res; 2003; 23(2C):1951-4. PubMed ID: 12820485
[TBL] [Abstract][Full Text] [Related]
8. Biotherapy with the pineal immunomodulating hormone melatonin versus melatonin plus aloe vera in untreatable advanced solid neoplasms.
Lissoni P; Giani L; Zerbini S; Trabattoni P; Rovelli F
Nat Immun; 1998; 16(1):27-33. PubMed ID: 9789122
[TBL] [Abstract][Full Text] [Related]
9. Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status.
Lissoni P; Barni S; Mandalà M; Ardizzoia A; Paolorossi F; Vaghi M; Longarini R; Malugani F; Tancini G
Eur J Cancer; 1999 Nov; 35(12):1688-92. PubMed ID: 10674014
[TBL] [Abstract][Full Text] [Related]
10. A phase II study of neuroimmunotherapy with subcutaneous low-dose IL-2 plus the pineal hormone melatonin in untreatable advanced hematologic malignancies.
Lissoni P; Bolis S; Brivio F; Fumagalli L
Anticancer Res; 2000; 20(3B):2103-5. PubMed ID: 10928160
[TBL] [Abstract][Full Text] [Related]
11. Antiprolactinemic approach in the treatment of metastatic breast cancer: a phase II study of polyneuroendocrine therapy with LHRH-analogue, tamoxifen and the long-acting antiprolactinemic drug cabergoline.
Lissoni P; Vaghi M; Villa S; Bodraska A; Cerizza L; Tancini G; Gardani GS
Anticancer Res; 2003; 23(1B):733-6. PubMed ID: 12680176
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
13. Neuroimmunotherapy of advanced solid neoplasms with single evening subcutaneous injection of low-dose interleukin-2 and melatonin: preliminary results.
Lissoni P; Barni S; Rovelli F; Brivio F; Ardizzoia A; Tancini G; Conti A; Maestroni GJ
Eur J Cancer; 1993; 29A(2):185-9. PubMed ID: 8422280
[TBL] [Abstract][Full Text] [Related]
14. A randomised study with subcutaneous low-dose interleukin 2 alone vs interleukin 2 plus the pineal neurohormone melatonin in advanced solid neoplasms other than renal cancer and melanoma.
Lissoni P; Barni S; Tancini G; Ardizzoia A; Ricci G; Aldeghi R; Brivio F; Tisi E; Rovelli F; Rescaldani R
Br J Cancer; 1994 Jan; 69(1):196-9. PubMed ID: 8286206
[TBL] [Abstract][Full Text] [Related]
15. Anticancer neuroimmunomodulation by pineal hormones other than melatonin: preliminary phase II study of the pineal indole 5-methoxytryptophol in association with low-dose IL-2 and melatonin.
Lissoni P; Fumagalli L; Paolorossi F; Rovelli F; Roselli MG; Maestroni GJ
J Biol Regul Homeost Agents; 1997; 11(3):119-22. PubMed ID: 9498162
[TBL] [Abstract][Full Text] [Related]
16. Neuroimmunomodulation in medical oncology: application of psychoneuroimmunology with subcutaneous low-dose IL-2 and the pineal hormone melatonin in patients with untreatable metastatic solid tumors.
Lissoni P; Brivio F; Fumagalli L; Messina G; Vigoré L; Parolini D; Colciago M; Rovelli F
Anticancer Res; 2008; 28(2B):1377-81. PubMed ID: 18505083
[TBL] [Abstract][Full Text] [Related]
17. Is there a role for melatonin in supportive care?
Lissoni P
Support Care Cancer; 2002 Mar; 10(2):110-6. PubMed ID: 11862501
[TBL] [Abstract][Full Text] [Related]
18. Randomized study with the pineal hormone melatonin versus supportive care alone in advanced nonsmall cell lung cancer resistant to a first-line chemotherapy containing cisplatin.
Lissoni P; Barni S; Ardizzoia A; Paolorossi F; Crispino S; Tancini G; Tisi E; Archili C; De Toma D; Pipino G
Oncology; 1992; 49(5):336-9. PubMed ID: 1382256
[TBL] [Abstract][Full Text] [Related]
19. Biological and clinical results of a neuroimmunotherapy with interleukin-2 and the pineal hormone melatonin as a first line treatment in advanced non-small cell lung cancer.
Lissoni P; Tisi E; Barni S; Ardizzoia A; Rovelli F; Rescaldani R; Ballabio D; Benenti C; Angeli M; Tancini G
Br J Cancer; 1992 Jul; 66(1):155-8. PubMed ID: 1322155
[TBL] [Abstract][Full Text] [Related]
20. Modulation of anticancer cytokines IL-2 and IL-12 by melatonin and the other pineal indoles 5-methoxytryptamine and 5-methoxytryptophol in the treatment of human neoplasms.
Lissoni P
Ann N Y Acad Sci; 2000; 917():560-7. PubMed ID: 11268384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
